Themis Medicare share news, announcements and annual reports
NSE: THEMISMEDBSE: 530199Pharmaceuticals & BiotechnologySmall Cap
Themis Medicare Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Apr 2007 on NSE
Last close ₹97.52down ₹0.92 (0.93%)BSE ₹97.50
Share price at the NSE close on 29 Oct 2026. Previous close ₹98.44.
29 Oct: open ₹100.45, high ₹102.03, low ₹95.35
52-week range of traded prices to 29 Oct 2026
₹64.95Low, 30 Mar 2026₹140.60High, 7 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹898 Cr1,570th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.47
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹92 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.25
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.51%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹92 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −13.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −10.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 51,63047.8% delivered
Themis Medicare disputes and clarifications
33 filed, newest first.
Sep 2026
7 Sep · Legal
The exchange asked on 7 Sep 2026
Jun 2026
23 Jun · Legal
The exchange asked on 22 Jun 2026
Nov 2024
19 Nov · Legal
The exchange asked on 18 Nov 2024
Sep 2024
13 Sep · Legal
The exchange asked on 12 Sep 2024
Jul 2024
5 Jul · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 06-Jun-2024, regarding appointment of Mr. Nikunt Kirit Raval as an Additional Non-Executive Independent Director of the Company w.e.f. June 06, 2024. On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.
Oct 2023
Sep 2023
26 Sep · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 10-Aug-2023, regarding " Themis Medicare Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2023.".On basis of above the Company is required to clarify following:1. Name of the target entity, details in brief such as size, turnover etc; 2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; 3. Industry to which the entity being acquired belongs; 4. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); 5. Brief details of any governmental or regulatory approvals required for the acquisition; 6. Indicative time period for completion of the acquisition; 7. Cost of acquisition or the price at which the shares are acquired; 8. Nature of consideration - whether cash consideration or share swap and details of the same; 9. Percentage of shareholding / control acquired and / or number of shares acquired; 10. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). The response of the Company is awaited.
Feb 2023
8 Feb · Legal
Exchange has sought clarification from Themis Medicare Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Dec 2022
19 Dec · Legal
Significant movement in price has been observed in Themis Medicare Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Feb 2022
15 Feb · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 11-Feb-2022, regarding Appointment of Secretarial Auditor. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Dec 2021
27 Dec · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 23-Dec-2021, regarding regarding Incorporation of New Subsidiary.On basis of above the Company is required to clarify following -1. Industry to which the entity being formed belongs;2. Objects and effects of formation(including but not limited to, disclosure of reasons for formation of target entity, if its business is outside the main line of business of the listed entity);3. Cost of acquisition(subscription amount) or the price at which the shares are acquired;4. Nature of consideration - whether cash consideration or share swap and details of the same;5. Percentage of shareholding / control acquired and / or number of shares acquired.The response of the Company is awaited.
Jun 2021
May 2021
31 May · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 27-May-2021, regarding M/s. B.J. D. Nanabhoy & Co. - Cost Accountant as the Cost Auditors. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment) The response of the Company is awaited.8 May · Legal
The exchange asked on 7 May 2021
Apr 2020
17 Apr · Legal
The exchange asked on 16 Apr 2020
Sep 2019
30 Sep · Legal
The exchange asked on 27 Sep 2019
Jul 2019
18 Jul · Legal
The exchange asked on 18 Jul 2019
Oct 2017
Sep 2017
29 Sep · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 27-Sep-2017, regarding "Outcome of Board Meeting held on September 27, 2017." This may be taken as compliance under the Listing Regulations.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);2. Area of agreement/JV;3. Domestic/international;4. Share exchange ratio / JV ratio;5. Scope of business operation of agreement / JV6. Details of consideration paid / received in agreement / JV;7. Significant terms and conditions of agreement / JV in brief;8. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arms length";9. Size of the entity(ies);10. Rationale and benefit expected.The response of the Company is awaited.
Aug 2017
22 Aug · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 21-Aug-2017, regarding "Outcome of Board Meeting held on August 21, 2017. The Company has appointed Mr. Sangameshwar Iyer as Company Secretary & Compliance officer of the Company with effect from 21st August 2017 to fill the vacancy caused by cessation of Mr. Prakash D. Naringrekar.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Feb 2017
14 Feb · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 14-Feb-2017, regarding "Themis Medicare Limited has informed the Exchange regarding Outcome of Board Meeting held on February 14, 2017.". On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;2. Brief profile (in case of appointment);3. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
Aug 2016
17 Aug · Legal
Exchange has sought clarification from Themis Medicare Limited with respect to announcement dated 11-Aug-2016, regarding "Themis Medicare Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on August 11, 2016. The board of directors of the Company has approved the following -Mr. Tushar J. Dalal will assume the position of Chief Financial Officer of the Company with effect from October 01, 2016'On basis of above the Company is required to clarify following:1. Reason for change viz. appointment, resignation, removal, death or otherwise;2. Date of appointment/cessation (as applicable) & term of appointment;3. Brief profile (in case of appointment);4. Dsclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
Apr 2016
1 Apr · Legal
Exchange has sought clarification from the company with respect to appointment of Mrs. Reena S. Patel as an Additional Independent Director on the Board of Directors of the CompanyOn basis of above the Company is required to clarify following:1. Brief profile of director;2. Date of appointment & term of appointment; 3. Disclosure of relationships between directors.The response of the Company is awaited.